Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (Prometheus) announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.
